Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
EPapchem is a specialized biotechnology company and contract research organization (CRO) based in Suzhou, China, dedicated to the field of Targeted Protein Degradation (TPD). The company provides a comprehensive platform for the discovery and development of Proteolysis Targeting Chimeras (PROTACs) and molecular glues, offering an extensive library of over 10,000 TPD-related building blocks. Their product portfolio includes a wide range of E3 ligase ligands, such as those for Cereblon and Von Hippel-Lindau, along with diverse linkers and functionalized precursors. Beyond supplying chemical components, EPapchem offers integrated services including custom synthesis, medicinal chemistry optimization, and TPD library construction. By addressing the complex chemistry required for effective protein degradation, the company supports global pharmaceutical partners in targeting previously undruggable proteins across oncology and immunology.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on EPapchem.